Before the House of Representatives had even passed the bill that guts the Affordable Care Act, President Obama had already announced he would veto it. And now he has made good on that promise.
Before the House of Representatives had even passed the bill that guts the Affordable Care Act (ACA), President Obama had already announced he would veto it. And now he has made good on that promise.
The Senate had passed the bill in December, despite the president’s vow that should it make it to his desk, he would veto the bill. On Wednesday, the House voted 240-181, almost entirely along party lines, to pass the legislation that essentially repeals the ACA.
"This legislation would cost millions of hard-working middle-class families the security of affordable health coverage they deserve," Obama wrote in his veto message. "Reliable health care coverage would no longer be a right for everyone: it would return to being a privilege for a few."
While House Speaker Paul Ryan quipped in a statement that it was no surprise “someone named Obama vetoed a bill appealing Obamacare,” the president noted that he believed the bill would cause harm to the health and financial security of Americans.
"Rather than re-fighting old political battles by once again voting to repeal basic protections that provide security for the middle class, members of Congress should be working together to grow the economy, strengthen middle-class families, and create new jobs," Obama wrote.
While Ryan vowed that he would hold an override vote when the bill goes back to Congress, Republicans do not have enough votes. However, he added that if a Republican is sitting in the White House next year, this bill will get signed into law.
“The idea that Obamacare is the law of the land for good is a myth,” he said in a statement. “This law will collapse under its own weight, or it will be repealed. Because all those rules and procedures Senate Democrats have used to block us from doing this? That's all history.”
he National Council of Asian Pacific Americans leading the way.
,”
National Director Christopher Kang
“We strongly support the President’s veto so that our communities can continue to have access to health care resources. "We are disappointed in yet another attack from Republicans in Congress to repeal the ACA, which has already benefitted millions."
Already, healthcare organizations are stating their support for the president's action with t
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More